2020-2027 Analysis and Review Liraglutide Injection Market

Liraglutide Injection Market

Liraglutide Injection Market By Clinical Application (Type 2 Diabetes, Obesity and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

22-06-2020 REP-HC-5123 40 Tables 120 pages Format

The liraglutide injection market was valued at USD 5,062.0 Mn by 2019. Rising prevalence of type 2 diabetes worldwide primarily drives the liraglutide injection market growth. Additionally, the growing incidence of obesity among the young population across the globe further accentuates the market growth.

Liraglutide Injection Market

Liraglutide is basically a synthetic analog of human glucagon-like peptide-1(GLP-1) and is considered as a GLP-1 receptor agonist, it is 97% homologous to the native GLP-1 by substituting the arginine in the place of lysine at the position of 34. In January 2010 it received approval from the FDA for the management of type 2 diabetes and is currently the sole property of Novo Nordisk A/S.

The major segments related to the liraglutide injection market are: 

By Clinical Application (2017–2027; US$ Mn)

Type 2 Diabetes

Obesity

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global liraglutide injection market
  • The overall segmentation of the liraglutide injection market, by clinical application, distribution channel, and geography is minutely studied. Type 2 diabetes and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
  • Rising prevalence of type 2 diabetes worldwide
  • The recent approval by global healthcare agencies for the use of liraglutide in the management of obesity across the globe will further accentuate the market growth

Report gist?

  • The study of the global liraglutide injection market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the biopharmaceutical manufacturers actively engaged in the production and marketing of liraglutide injection due to the rising prevalence of type 2 diabetes worldwide
  • The report will physicians and dieticians in prescribing liraglutide injection in patients undergoing obesity management program
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to liraglutide injection market
  • Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Type 2 diabetes is representing the largest market share in the clinical application for the liraglutide injection market. According to the latest statistics provided by the International Diabetes Federation (IDF), it is estimated that in 2019 approximately 463 million adult populations are suffering from type 2 diabetes. The disease progression is a combination of both genetic and lifestyle disorders. The pathophysiology of type 2 diabetes is attributed to 3 clinical factors which are decreased insulin secretion, elevated hepatic glucose production, and increased insulin resistance, etc. Obesity is keen to register impressive market growth during the forecast period on account of the increasing consumption of junk food, alcohol, tobacco, and sedentary lifestyle among young adult population worldwide. As per the latest information provided by the World Health Organization (WHO), approximately 13% of the global population is anticipated to be the suffering with obesity, further clinical investigation states the prevalence rate of 11% and 15% in the men and women population respectively.

Hospital pharmacy is currently leading the distribution channel segment in the liraglutide injection market. High risk of disease progression of pancreatitis with the injudicious use of liraglutide injection, makes it imperative for the precise dispensing of medicine under the supervision of a hospital pharmacist. It is expected that in the near future retail pharmacy will be showcasing exemplary market growth in the developing regions of the world owing to the provision of cheap medicines due to the imposition of government subsidy for essential medicines.

North America is presently dominating the geography segment for the liraglutide injection market. Rising prevalence of type 2 diabetes primarily drives the liraglutide market growth in the region. As per the latest research citings presented by the American Diabetes Association (ADA), approximately 9% of the population in the U.S. is suffering from type 2 diabetes. Additionally, the supportive regulatory environment provided by the USFDA in the sale and marketing of liraglutide injection further propels the market growth in the region. Europe is considered as the second-largest regional segment in the liraglutide injection market. The rising prevalence of obesity in the young population determines the liraglutide injection market growth in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment in the liraglutide market on account of the developing healthcare infrastructure and rising public health awareness regarding the therapeutic efficacy of liraglutide in the management of type 2 diabetes and obesity prevalence in the Asia Pacific region.

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.